secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pyxis Oncology, Inc. (PYXS)
CIK:        0001782223
Form:       8-K
Filed at:   2022-08-15T23:59:59+00:00
Accession:  0000950170-22-017220
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pyxis Oncology Q2 net loss $25.6M, cash $207M; stops PYX-202, prioritizes two lead programs
--------------------------------------------------------------------------------

- Cash $207M as of Aug 15, 2022; expected to fund operations through second half of 2024.
- Q2 net loss $25.6M ($0.79/sh) vs $8.1M ($5.54/sh) in 2021; R&D expense $17.2M (from $3.2M).
- Prioritizes PYX-201 (anti-EDB ADC) and PYX-106 (anti-Siglec-15 mAb) for IND filings in H2 2022.
- Ceases development of PYX-202 (anti-DLK1 ADC) after toxicology data; pauses PYX-203 and PYX-102.
- Appoints Dr. Rachel Humphrey to Board; receives option grant for 236,220 shares at $2.91.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1782223/000095017022017220/0000950170-22-017220-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1782223/000095017022017220/pyxs-20220815.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-017220

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer